{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:45Z","timestamp":1790188185391,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>While postoperative adjuvant chemotherapy (AC) is generally recommended for intrahepatic cholangiocarcinoma (ICC), its benefit remains debated. This study aimed to identify patients that may benefit from AC following liver resection of ICC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients who underwent liver resection for ICC between 2000 and 2023 were identified from an international multi-institutional database. Individual multivariable Cox models were used to evaluate the interaction between each prognostic factor and the effect of AC on survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1412 patients, 431 (30.5%) received AC. Both higher tumor burden score (TBS; hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.91\u20131.00; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.033) and metastatic lymph node status (HR 0.58, 95% CI 0.38\u20130.89; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.014) demonstrated interactions with the survival benefit from receipt of AC. Interaction plots highlighted how AC was associated with improved survival beyond a TBS of approximately 6. Notably, among 555 (39.3%) patients with TBS &lt;6 and N0 or Nx status, 5-year overall survival (OS) was no different between patients who received AC versus individuals who did not (55.1% [95% CI 48.9\u201362.1] vs. 58.7% [95% CI 49.8\u201369.2]; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.900). In contrast, among 857 (60.7%) patients with TBS \u22656 or N1 status, AC was associated with improved 5-year OS (30.7% [95% CI 26.2\u201336.0] vs. 33.0% [95% CI 26.9\u201340.5]; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.018).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>TBS and lymph node status may be useful in a multidisciplinary setting to inform decisions about AC planning for ICC patients following curative-intent resection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17013-5","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:59:54Z","timestamp":1739847594000},"page":"4341-4351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Jun","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamawit","family":"Woldesenbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujtaba","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cauchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir","family":"Maithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pulitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Aldrighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Poultsides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzzente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"7","key":"17013_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00432-010-0971-z","volume":"137","author":"AK Singal","year":"2011","unstructured":"Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma\u2013frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071\u20138. https:\/\/doi.org\/10.1007\/s00432-010-0971-z.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"12","key":"17013_CR2","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","volume":"21","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827\u201334. https:\/\/doi.org\/10.1245\/s10434-014-3828-x.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17013_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"7","key":"17013_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1777\u201387. https:\/\/doi.org\/10.1007\/s00268-019-04966-4.","journal-title":"World J Surg."},{"issue":"23","key":"17013_CR5","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.35.6519.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17013_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg."},{"issue":"2","key":"17013_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.hpb.2022.10.011","volume":"25","author":"Y Endo","year":"2023","unstructured":"Endo Y, Moazzam Z, Alaimo L, et al. Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy. HPB. 2023;25(2):229\u201338. https:\/\/doi.org\/10.1016\/j.hpb.2022.10.011.","journal-title":"HPB"},{"issue":"3","key":"17013_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11605-022-05558-9","volume":"27","author":"MM Munir","year":"2023","unstructured":"Munir MM, Ruff SM, Endo Y, et al. Does adjuvant therapy benefit low-risk resectable cholangiocarcinoma? An evaluation of the NCCN guidelines. J Gastrointest Surg. 2023;27(3):511\u201320. https:\/\/doi.org\/10.1007\/s11605-022-05558-9.","journal-title":"J Gastrointest Surg."},{"issue":"5","key":"17013_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study [published correction appears in Lancet Oncol. Lancet Oncol. 2019;20(5):663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol."},{"issue":"10372","key":"17013_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(22)02038-4.","journal-title":"Lancet."},{"issue":"3","key":"17013_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202. https:\/\/doi.org\/10.1002\/bjs.10776.","journal-title":"Br J Surg."},{"issue":"8","key":"17013_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367. https:\/\/doi.org\/10.1200\/JCO.18.00050.","journal-title":"J Clin Oncol."},{"issue":"9","key":"17013_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823\u201331. https:\/\/doi.org\/10.1001\/jamasurg.2020.1973.","journal-title":"JAMA Surg."},{"issue":"2","key":"17013_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC cancer staging manual: continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer staging. CA: A Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA: A Cancer J Clin"},{"issue":"1","key":"17013_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","volume":"267","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Morioka D, Conci S, et al. The tumor burden score: a New, \u201cMetro-ticket\u201d prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132\u201341. https:\/\/doi.org\/10.1097\/SLA.0000000000002064.","journal-title":"Ann Surg."},{"issue":"1","key":"17013_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000004808","volume":"274","author":"M Nagino","year":"2021","unstructured":"Nagino M, DeMatteo R, Lang H, et al. Proposal of a new comprehensive notation for hepatectomy: the \u201cnew world\u201d terminology. Ann Surg. 2021;274(1):1\u20133. https:\/\/doi.org\/10.1097\/SLA.0000000000004808.","journal-title":"Ann Surg."},{"issue":"6","key":"17013_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r","volume":"18","author":"S van Buuren","year":"1999","unstructured":"van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681\u201394. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6%3c681::aid-sim71%3e3.0.co;2-r.","journal-title":"Stat Med."},{"issue":"1","key":"17013_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.hpb.2020.07.007","volume":"23","author":"S B\u00fcttner","year":"2021","unstructured":"B\u00fcttner S, Galjart B, Beumer BR, et al. Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. HPB. 2021;23(1):25\u201336. https:\/\/doi.org\/10.1016\/j.hpb.2020.07.007.","journal-title":"HPB"},{"issue":"3","key":"17013_CR19","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1097\/SLA.0000000000004150","volume":"275","author":"V Raman","year":"2022","unstructured":"Raman V, Jawitz OK, Farrow NE, et al. The relationship between lymph node ratio and survival benefit with adjuvant chemotherapy in node-positive esophageal adenocarcinoma. Ann Surg. 2022;275(3):e562\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000004150.","journal-title":"Ann Surg."},{"issue":"22","key":"17013_CR20","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1002\/cncr.28312","volume":"119","author":"SK Maithel","year":"2013","unstructured":"Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013;119(22):3929\u201342. https:\/\/doi.org\/10.1002\/cncr.28312.","journal-title":"Cancer."},{"issue":"6","key":"17013_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137.","journal-title":"JAMA Surg."},{"issue":"1","key":"17013_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/jcm10010104","volume":"10","author":"EW Beal","year":"2020","unstructured":"Beal EW, Cloyd JM, Pawlik TM. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med. 2020;10(1):104. https:\/\/doi.org\/10.3390\/jcm10010104.","journal-title":"J Clin Med."},{"issue":"39","key":"17013_CR23","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/fon-2023-0098","volume":"19","author":"K Merath","year":"2023","unstructured":"Merath K, Tiwari A, Parikh AA, Pawlik TM. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol. 2023;19(39):2607\u201321. https:\/\/doi.org\/10.2217\/fon-2023-0098.","journal-title":"Future Oncol."},{"issue":"4","key":"17013_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.21037\/hbsn-2021-12","volume":"10","author":"JM Cloyd","year":"2021","unstructured":"Cloyd JM, Pawlik TM. Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surg Nutr. 2021;10(4):515\u20137. https:\/\/doi.org\/10.21037\/hbsn-2021-12.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"5","key":"17013_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.21037\/hbsn.2019.06.12","volume":"9","author":"AM Altman","year":"2020","unstructured":"Altman AM, Kizy S, Marmor S, et al. Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus? Hepatobiliary Surg Nutr. 2020;9(5):577\u201386. https:\/\/doi.org\/10.21037\/hbsn.2019.06.12.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"10","key":"17013_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.hpb.2017.06.008","volume":"19","author":"BN Reames","year":"2017","unstructured":"Reames BN, Bagante F, Ejaz A, et al. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB. 2017;19(10):901\u20139. https:\/\/doi.org\/10.1016\/j.hpb.2017.06.008.","journal-title":"HPB"},{"issue":"11","key":"17013_CR27","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1245\/s10434-015-4501-8","volume":"22","author":"JT Miura","year":"2015","unstructured":"Miura JT, Johnston FM, Tsai S, et al. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015;22(11):3716\u201323. https:\/\/doi.org\/10.1245\/s10434-015-4501-8.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17013_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejso.2019.11.499","volume":"46","author":"K Rangarajan","year":"2020","unstructured":"Rangarajan K, Simmons G, Manas D, Malik H, Hamady ZZ. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(4):684\u201393. https:\/\/doi.org\/10.1016\/j.ejso.2019.11.499.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"17013_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/jso.27314","volume":"128","author":"Y Endo","year":"2023","unstructured":"Endo Y, Rueda BO, Woldesenbet S, et al. The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases. J Surg Oncol. 2023;128(4):560\u20138. https:\/\/doi.org\/10.1002\/jso.27314.","journal-title":"J Surg Oncol."},{"issue":"9","key":"17013_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108532","volume":"50","author":"J Kawashima","year":"2024","unstructured":"Kawashima J, Chatzipanagiotou OP, Tsilimigras DI, et al. Preoperative and postoperative predictive models of early recurrence for colorectal liver metastases following chemotherapy and curative-intent one-stage hepatectomy. Eur J Surg Oncol. 2024;50(9):108532. https:\/\/doi.org\/10.1016\/j.ejso.2024.108532.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"17013_CR31","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.hpb.2023.07.901","volume":"25","author":"Y Endo","year":"2023","unstructured":"Endo Y, Moazzam Z, Alaimo L, et al. Modified integrated tumor burden, liver function, systemic inflammation, and tumor biology score to predict long-term outcomes after resection for hepatocellular carcinoma. HPB. 2023;25(12):1484\u201393. https:\/\/doi.org\/10.1016\/j.hpb.2023.07.901.","journal-title":"HPB"},{"issue":"4","key":"17013_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","volume":"272","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg. 2020;272(4):574\u201381. https:\/\/doi.org\/10.1097\/SLA.0000000000004346.","journal-title":"Ann Surg."},{"issue":"4","key":"17013_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","volume":"272","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg. 2020;272(4):574\u201381. https:\/\/doi.org\/10.1097\/SLA.0000000000004346.","journal-title":"Ann Surg."},{"issue":"3","key":"17013_CR34","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1245\/s10434-022-12463-7","volume":"30","author":"L Alaimo","year":"2023","unstructured":"Alaimo L, Moazzam Z, Brown ZJ, et al. Application of hazard function to investigate recurrence of intrahepatic cholangiocarcinoma after curative-intent liver resection: a novel approach to characterize recurrence. Ann Surg Oncol. 2023;30(3):1340\u20139. https:\/\/doi.org\/10.1245\/s10434-022-12463-7.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17013_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4143\/crt.2023.784","volume":"56","author":"S Choi","year":"2024","unstructured":"Choi S, Seo S, Lee JH, et al. Impact of patient sex on adverse events and unscheduled utilization of medical services in cancer patients undergoing adjuvant chemotherapy: a multicenter retrospective cohort study. Cancer Res Treat. 2024;56(2):404\u201313. https:\/\/doi.org\/10.4143\/crt.2023.784.","journal-title":"Cancer Res Treat."},{"key":"17013_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2018.02.011","volume":"119","author":"H Borghaei","year":"2018","unstructured":"Borghaei H, Yim YM, Guerin A, et al. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer. 2018;119:112\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2018.02.011.","journal-title":"Lung Cancer."},{"issue":"1","key":"17013_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2020.10.477","volume":"32","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Rulli E, Labianca R, et al. Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial. Ann Oncol. 2021;32(1):66\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.477.","journal-title":"Ann Oncol."},{"issue":"6","key":"17013_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","volume":"27","author":"D Sargent","year":"2009","unstructured":"Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.19.5362.","journal-title":"J Clin Oncol."},{"key":"17013_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jso.28007","author":"J Kawashima","year":"2024","unstructured":"Kawashima J, Akabane M, Endo Y, et al. Recurrence timing and risk following curative resection of colorectal liver metastases: insights from a hazard function analysis. J Surg Oncol. 2024. https:\/\/doi.org\/10.1002\/jso.28007.","journal-title":"J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17013-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:15:23Z","timestamp":1746288923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17013-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17013"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17013-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, Fran\u00e7ois Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ruzzente, Todd W. Bauer, Ana Gleisner, Hugo Marques, Bas Groot Koerkamp, Itaru Endo, and Timothy M. Pawlik have no conflicts of interest or disclaimers to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}